Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)‘s stock had its “outperform” rating restated by stock analysts at Wells Fargo & Company in a report issued on Thursday. They currently have a $177.00 price objective on the specialty pharmaceutical company’s stock, down from their previous price objective of $178.00. Wells Fargo & Company’s target price would suggest a potential upside of 23.86% from the company’s current price.

JAZZ has been the topic of several other reports. Janney Montgomery Scott restated a “buy” rating and set a $192.00 price objective (up from $180.00) on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday. Deutsche Bank AG set a $175.00 price objective on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Wednesday. Cowen and Company restated an “outperform” rating and set a $190.00 price objective on shares of Jazz Pharmaceuticals PLC in a research note on Wednesday. Leerink Swann raised their price objective on Jazz Pharmaceuticals PLC from $169.00 to $170.00 and gave the stock a “buy” rating in a research note on Tuesday, July 4th. Finally, Royal Bank Of Canada set a $210.00 price objective on Jazz Pharmaceuticals PLC and gave the stock a “buy” rating in a research note on Tuesday, June 27th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus target price of $182.96.

Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at 142.90 on Thursday. The stock has a 50 day moving average of $155.68 and a 200-day moving average of $146.56. The firm has a market capitalization of $8.58 billion, a PE ratio of 21.59 and a beta of 1.10. Jazz Pharmaceuticals PLC has a one year low of $95.80 and a one year high of $163.75.

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, August 8th. The specialty pharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.85 by $0.13. Jazz Pharmaceuticals PLC had a return on equity of 23.80% and a net margin of 25.69%. The firm had revenue of $394.39 million for the quarter, compared to the consensus estimate of $410.83 million. During the same quarter last year, the business earned $2.67 earnings per share. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, equities analysts predict that Jazz Pharmaceuticals PLC will post $11.02 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/jazz-pharmaceuticals-plc-jazz-earns-outperform-rating-from-wells-fargo-company/1467494.html.

In other news, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction on Monday, May 15th. The stock was sold at an average price of $152.98, for a total transaction of $30,596.00. Following the transaction, the executive vice president now directly owns 22,623 shares of the company’s stock, valued at $3,460,866.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Suzanne Sawochka Hooper sold 4,580 shares of the firm’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $160.00, for a total value of $732,800.00. Following the transaction, the executive vice president now directly owns 32,322 shares in the company, valued at $5,171,520. The disclosure for this sale can be found here. Insiders have sold 10,600 shares of company stock worth $1,641,720 over the last three months. Corporate insiders own 4.30% of the company’s stock.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in JAZZ. Dimensional Fund Advisors LP raised its position in Jazz Pharmaceuticals PLC by 0.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 147,511 shares of the specialty pharmaceutical company’s stock worth $16,082,000 after buying an additional 408 shares during the last quarter. Teachers Advisors LLC raised its position in Jazz Pharmaceuticals PLC by 9.5% in the fourth quarter. Teachers Advisors LLC now owns 151,056 shares of the specialty pharmaceutical company’s stock worth $16,470,000 after buying an additional 13,119 shares during the last quarter. Bank of Montreal Can raised its position in Jazz Pharmaceuticals PLC by 171.4% in the first quarter. Bank of Montreal Can now owns 45,770 shares of the specialty pharmaceutical company’s stock worth $6,644,000 after buying an additional 28,904 shares during the last quarter. Gateway Investment Advisers LLC raised its position in Jazz Pharmaceuticals PLC by 13.0% in the first quarter. Gateway Investment Advisers LLC now owns 73,395 shares of the specialty pharmaceutical company’s stock worth $10,652,000 after buying an additional 8,418 shares during the last quarter. Finally, Capital Impact Advisors LLC raised its position in Jazz Pharmaceuticals PLC by 60.4% in the first quarter. Capital Impact Advisors LLC now owns 9,182 shares of the specialty pharmaceutical company’s stock worth $1,333,000 after buying an additional 3,456 shares during the last quarter. 86.43% of the stock is currently owned by hedge funds and other institutional investors.

About Jazz Pharmaceuticals PLC

Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.

Analyst Recommendations for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.